{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.07","upperLimit":"8.28","value":"6.06"},{"comment":"NA= not reached. Insufficient number of participants with events to calculate the median and upper limit of the 95% confidence interval.","groupId":"OG001","lowerLimit":"2.56","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"description":"DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + cetuximab. Encorafenib: Orally, once daily. Cetuximab: Standard of care.","id":"OG000","title":"Phase 3: Doublet Arm"},{"description":"Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab. Cetuximab: Standard of care. Irinotecan: Standard of care. Folinic Acid: Standard of care. 5-Fluorouracil: Standard of care. Following protocol amendment, eligible participants could crossover to receive either triplet or doublet regimen.","id":"OG001","title":"Phase 3:Control Arm"}],"paramType":"MEDIAN","populationDescription":"The Phase 3 Response Efficacy Set consisted of the first 330 participants randomized into the Phase 3 portion of the study and any additional participants randomized on the same day as the 330th randomized participant. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From time of response to PD or death due to underlying disease (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)","title":"(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR","type":"SECONDARY","unitOfMeasure":"Months"}